Collegium Pharmaceutical Inc’s filing revealed that its DIRECTOR RITA BALICE-GORDON acquired Company’s shares for reported $0.17 million on Dec 05 ’25. In the deal valued at $47.03 per share,3,650 shares were bought.
Then, Dreyer Scott sold 17,600 shares, generating $847,855 in total proceeds. Upon selling the shares at $48.17, the EVP & Chief Commercial Officer now owns 103,613 shares.
Before that, Balice-Gordon Rita J. sold 3,650 shares. Collegium Pharmaceutical Inc shares valued at $171,673 were divested by the Director at a price of $47.03 per share. As a result of the transaction, Balice-Gordon Rita J. now holds 52,629 shares, worth roughly $2.53 million.
Barclays initiated its Collegium Pharmaceutical Inc [COLL] rating to an Overweight in a research note published on December 09, 2025; the price target was $58. A number of analysts have revised their coverage, including Needham’s analysts, who increased its forecast for the stock in early January from “a Hold” to “a Buy”. H.C. Wainwright also remained covering COLL and has increased its forecast on July 30, 2024 with a “Buy” recommendation from previously “Neutral” rating. Jefferies revised its rating on June 07, 2024. It rated COLL as “a Buy” which previously was an “a Hold”.
Price Performance Review of COLL
On Monday, Collegium Pharmaceutical Inc [NASDAQ:COLL] saw its stock jump 5.73% to $48.15. Over the last five days, the stock has gained 5.41%. Collegium Pharmaceutical Inc shares have risen nearly 44.42% since the year began. Nevertheless, the stocks have risen 4.00% over the past one year.
How much short interest is there in Collegium Pharmaceutical Inc?
A steep rise in short interest was recorded in Collegium Pharmaceutical Inc stocks on 2025-12-31, dropping by -0.46 million shares to a total of 5.42 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 5.88 million shares. There was a decline of -8.55%, which implies that there is a negative sentiment for the stock.
